Pharmacovigilance Methods. The Spectrum of PV
|
|
|
- Karin Montgomery
- 6 years ago
- Views:
Transcription
1 Pharmacovigilance Methods The Spectrum of PV
2 PV Methods: which one? Cohort Event Monitoring Spontaneous Reporting EHR Mining Intensified ADR Reporting Targeted Reporting Record Linkage Geraldine Hill, Uppsala Monitoring Centre 2
3 What is your objective? To establish a functional reporting system to monitor the safety of all medicines To learn more about the safety profile of new medicines in the early post-marketing phase To learn more about the ADR profile of a specific medicine(s) in your population To estimate the incidence of a known ADR to a specific medicine in your population To gather more information on the safety profile of a new chemical entity in early post-marketing phase To make use of existing electronic health records and registries to support pharmacovigilance activitites Geraldine Hill, Uppsala Monitoring Centre 3
4 PV Methods Spectrum Spontaneous Reporting Intensified ADR Reporting Targeted Reporting Cohort Event Monitoring EHR Mining Geraldine Hill, Uppsala Monitoring Centre 4
5 Spontaneous Reporting Objective: a functional ADR reporting system to monitor the safety of all medicines Voluntary submission of ICSRs by health professionals, pharmaceutical manufacturers (and patients) to the national pharmacovigilance centre Requires two initial steps: A patient or health professional 1. suspects that an undesirable medical event may have been caused by exposure to a medicine 2. reports the suspicion to the national pharmacovigilance centre Geraldine Hill, Uppsala Monitoring Centre 5
6 Spontaneous Reporting: what to report? Developing Pharmacovigilance System All suspected ADRs Encourage a culture of ADR reporting Build PV capacity Develop a profile of ADRs experienced with locally used medicines If in doubt, report! Geraldine Hill, Uppsala Monitoring Centre 6
7 Spontaneous Reporting: what to report? Established Pharmacovigilance System May wish to restrict what is reported e.g. MHRA and EMA countries limit reporting to: All suspected ADRs for new medicines All suspected ADRs occurring in children, even if a medicine has been used off-label All serious* suspected ADRs for established vaccines and medicines, including unlicensed medicines, herbal remedies and medicines used off-label. * fatal, life-threatening, causing permanent disability, prolonging hospitalisation or medically significant If in doubt, report! Geraldine Hill, Uppsala Monitoring Centre 7
8 Spontaneous Reporting Pros Covers the whole population Includes all medicines Continual monitoring throughout lifecycle of a medicine Detects signals of new, rare or serious ADRs Most commonly used method Easiest method to establish Relatively inexpensive Least labour intensive Cons Inherent under-reporting Captures only suspected ADRs Reporting bias e.g. Seriousness, severity New medicine Advertising of product Publicity of specific ADR Denominator unknown Difficult to detect delayed ADRs & ADRs with high background incidence Geraldine Hill, Uppsala Monitoring Centre 8
9 Intensified ADR Reporting Objective: to enhance ADR reporting of specific medicines in early post-marketing phase Extension of Spontaneous Reporting Programme Black Triangle Scheme This medicinal product is subject to additional monitoring System in place in UK for many years; to be introduced in EU from Autumn List of medicines under additional reporting reviewed monthly Geraldine Hill, Uppsala Monitoring Centre 9
10 Intensified ADR Reporting Medicines under additional monitoring include: Medicines containing a new active substance Biological medicines Medicines given conditional approval or approved under exceptional circumstances Medicines that require additional studies (e.g. More data on long term use or on a rare side effect seen in clinical trials) Geraldine Hill, Uppsala Monitoring Centre 10
11 Targeted Spontaneous Reporting Objective: To learn more about the ADR profile of a specific medicine(s) in your population or To estimate the incidence of a known ADR to a specific medicine in your population Geraldine Hill, Uppsala Monitoring Centre 11
12 Targeted Reporting Specific ADR All ADRs Specific Medicine(s) Specific Clinics Specific Population Geraldine Hill, Uppsala Monitoring Centre 12
13 Targeted Reporting TSR of suspected ADRs to ARVs, AMPATH, Eldoret, Kenya AMPATH (Academic Model Providing Access to Healthcare) Partnership between Moi University School of Medicine, Moi Teaching and Referral Hospital and a consortium of US medical schools led by Indiana University. Treats over 125,000 HIV-positive patients at 53 sites in and around Eldoret, Western Kenya. Focusing on treatment-threatening ADRs (change or discontinuation of treatment) Investigating different methods of collecting ADR data, including: Spontaneous reporting of suspected ADR by clinician Spontaneous reporting of suspected ADR by pharmacist Interview by pharmacist of random sample of patients Interview by peer of random sample of patients Pharmacy dispensing data (to assess under-reporting) Geraldine Hill, Uppsala Monitoring Centre 13
14 TSR pilot project in Uganda: Monitoring Medicines Project Collaboration between National Pharmacovigilance Centre and AIDS Control Programme Objectives include: Targeted Reporting To monitor renal toxicities related to use of Tenofovir (TDF)-based regimens in adults To monitor ADRs related to use of Zidovudine (AZT) for PMTCT To enhance pharmacovigilance in AIDS control programme Screening for renal toxicity follows routine practice ADRs are reported spontaneously if observed Geraldine Hill, Uppsala Monitoring Centre 14
15 Cohort Event Monitoring (CEM) Objective: To gather more information on the safety profile of a new chemical entity in early post-marketing phase New class of medicine Medicine related to class of medicine that has previously caused problems Potentially significant adverse event observed during pre- or post-marketing surveillance (SR) Geraldine Hill, Uppsala Monitoring Centre 15
16 Decision to monitor influenced by: A need for more safety data (in general or in relation to a particular clinical use) Expected long-term use Expected widespread use Where increase in risk/benefit ratio would be unacceptable (e.g. life-style drugs ) One of several treatment options for a disease, where other treatment options are considered safe and effective. Geraldine Hill, Uppsala Monitoring Centre 16
17 Cohort Event Monitoring (CEM) A prospective, longitudinal, observational, cohort study of adverse events associated with one or more monitored medicines Geraldine Hill, Uppsala Monitoring Centre 17
18 Cohort Event Monitoring Prospective Longitudinal (Inceptional) Observational Cohort Adverse events Real-time monitoring Over a period of time From start of treatment Does not interfere with patient management Defined group of patients Any new clinical experience (favourable or unfavourable) that is worthy of a record in the patient s file, regardless of its severity and without judgement on its causality Monitored medicine Specific medicine(s) Geraldine Hill, Uppsala Monitoring Centre 18
19 Cohort Event Monitoring Records ALL CLINICAL EVENTS not just suspected adverse reactions A time-limited programme to complement other PV activities; not intended to replace spontaneous reporting Geraldine Hill, Uppsala Monitoring Centre 19
20 Cohort Event Monitoring Patient Health Care Provider Event Recording Hospitals & Clinics Data Entry Staff Data Entry Pharmacovigilance Centre Medical Assessor Event Causality Assessment Data Collation Signal? Expert Advisory Committee Signal Evaluation Uppsala Monitoring Centre Communication Geraldine Hill, Uppsala Monitoring Centre 20 Stakeholders
21 CEM enables us to: Characterise known reactions Detect signals of unrecognised reactions Identify interactions with other medicines and TCAMs Detect inefficacy of medicine Assess safety in pregnancy & lactation Measure risk (including comparative risk) Identify risk factors for ADRs Geraldine Hill, Uppsala Monitoring Centre 21
22 CEM Programmes (CemFlow) HIV Malaria Belarus RCETH CEM for ARV medicines in Republic of Belarus Ghana FDA (Ghana) CEM Malaria (WHO) INESS CEM Malaria (AMFm) INESS International CEM Ghana Kenya PPB CEM-AL Kenya Nigeria NAFDAC CEM for Malaria (Pilot) CEM for Malaria (Scale-up) Tanzania TFDA TANCEM (ALu) INESS Zimbabwe Medicines Control Authority of Zimbabwe TANCEM DHA/PPQ INESS International CEM Tanzania ZimCemFlow ACT Geraldine Hill, Uppsala Monitoring Centre 22
23 Monitored Antimarlarial Medicines Ghana CEM Malaria (WHO) All antimalarials CEM Malaria (AMFm) AL, AsAq INESS International CEM Ghana AqAr Kenya CEM-AL Kenya AL Nigeria CEM for Malaria (Pilot) AL, AsAq CEM for Malaria (Scale-up) AL, AsAq Tanzania TANCEM (ALu) AL TANCEM DHA/PPQ DP INESS International CEM Tanzania AL Zimbabwe ZimCemFlow ACT AL AL artemether+lumefantrin AsAq artesunate+amodiaquine AqAm amodiaquine+artemether DP dihydroartemisinin+piperaquine Geraldine Hill, Uppsala Monitoring Centre 23
24 Cohort Event Monitoring Pros Early detection of signals of unsuspected ADRs Denominator information allows incidence rates of ADRs to be calculated Near complete profile of AEs/ADRs for medicine of interest Assessment of risk; identification of risk factors; between drug comparisons Pregnancy outcomes Cons More labour intensive than SR or TSR More costly Much data collected most of which represents background noise New to health professionals and PV Centres Training required LTFU may be substantial and needs to be actively managed Deaths recorded Geraldine Hill, Uppsala Monitoring Centre 24
25 Workload considerations Example: Antimalarial Monitoring Target size of cohort: 3000 patients (3300 patients to allow for 10% LTFU); 10 sites (330 patients per site) 5 patients per week, 2 visits over 1 week 660 data collection forms (DCFs) from 1 monitoring site 6600 DCFs in total Data collection forms Week Geraldine Hill, Uppsala Monitoring Centre 25
26 Workload considerations Example: ARV Monitoring Target size of cohort: 3000 patients (3300 patients to allow for 10% LTFU); 10 sites (330 patients per site) 5 patients per week, 14 visits over 12 months (wk 0, 2, 6, (monthly)...50) 4620 reports from 1 monitoring site reports in total 70 Geraldine Hill, Uppsala Monitoring Centre 26
27 Electronic Health Record Mining Objective: make use of existing health records to supplement pharmacovigilance activities Electronic Health Records - a potentially rich source of ADR data Mining of the THIN data-base is currently being evaluated More to come on this later...! Geraldine Hill, Uppsala Monitoring Centre 27
28 PV Methods Spectrum Spontaneous Reporting Intensified ADR Reporting Targeted Reporting Cohort Event Monitoring EHR Mining Denominator unknown Denominator unknown Denominator known Denominator known Denominator known Denominator known Suspected ADRs Suspected ADRs Specific ADRs Suspected ADRs All Events All Events All medicines Specific medicines Cohort specific medicines Cohort specific medicines Cohort specific medicines All medicines Essential minimum reporting Early postmarketing phase of new drugs Incidence of a known ADR in a specific population Profile of ADRs for a specific medicine in a specific popn Post-marketing surveillance of a new chemical entity Making use of existing records to enhance PV WHO Programme for International Drug Monitoring UK/EU Black Triangle Scheme TSR of Tenofivir in Uganda; AMPATH Kenya ARVs CEM of new antimalarials (ACTs) PROTECT 3.10 Mining of THIN database Geraldine Hill, Uppsala Monitoring Centre 28
29 Comparing the methods Method Medicines Population Reports Spontaneous Reporting All medicines, life-cycle of product All exposed individuals but denominator unknown All ADRs Intensified ADR Reporting Specific medicines All exposed individuals but denominator unknown All ADRs Targeted Reporting Specific medicines Defined cohort Specific ADRs All ADRs Cohort Event Monitoring Specific medicines Defined cohort All Events EHR Mining All medicines Defined cohort All Events Geraldine Hill, Uppsala Monitoring Centre 29
30 Tack så mycket Uppsala Monitoring Centre Box 1051 SE Uppsala, Sweden Visiting address: Bredgränd 7, Uppsala tel fax website Geraldine Hill, Uppsala Monitoring Centre 30
Medicines Safety in WHO: promoting best practices in Pharmacovigilance. Dr Shanthi Pal Medicines Safety Programme Manager WHO (HQ)
Medicines Safety in WHO: promoting best practices in Pharmacovigilance Dr Shanthi Pal Medicines Safety Programme Manager WHO (HQ) 1 Birth of modern pharmacovigilance Thalidomide Phocomelia 1961 2 16th
REPORT ON MONITORING OF ADVERSE DRUG REACTIONS DUE TO ANTIMALARIAL USE IN TANZANIA
Doc. No. TFDA/DMC/CTPV/003 TANZANIA FOOD AND RUGS AUTHORITY REPORT ON MONITORING OF ADVERSE DRUG REACTIONS DUE TO ANTIMALARIAL USE IN TANZANIA 2006-2008 P. O. Box 77150, EPI Mabibo, Off Mandela Road, Dar
Dr Vibhu Paudyal Dr Kerry Wilbur Dr Mohamed Izham Dr Anas Hamad
Dr Vibhu Paudyal Dr Kerry Wilbur Dr Mohamed Izham Dr Anas Hamad Reporting adverse drug reactions (ADRs) QU Aberdeen WKH-HMC Doha Crossword puzzle Workshop overview Pharmacovigilance: introduction International
The Role of the Pharmacist in Pharmacovigilance A Regulatory Perspective
The Role of the Pharmacist in Pharmacovigilance A Regulatory Perspective Almath Spooner, Irish Medicines Board Pharmaceutical Society of Ireland National Pharmacy Summit, November 2008. Presentation Topics
Regulatory Aspects of Pharmacovigilance
Regulatory Aspects of Pharmacovigilance Deirdre Mc Carthy Pia Caduff-Janosa Training Course Uppsala 2012 Agenda Risk based approach to spontaneous reporting (incl clinical trials) -> Pia Caduff-Janosa
Pharmacovigilance. Training session for patients and consumers involved in EMA activities, 25 November Presented by: Priya Bahri
Pharmacovigilance Training session for patients and consumers involved in EMA activities, 25 November 2014 Presented by: Priya Bahri An agency of the European Union 2 Pharmacovigilance - the science concerned
Health Canada s NHP Vigilance Activities
Health Canada s NHP Vigilance Activities Canadian Health Food Association (CHFA) East October 3, 2013 Scott Sawler Director General Marketed Health Products Directorate Overview NHP Program & MHPD Activities
The EU Risk Management Plan - a tool to address the uncertainties at the time of approval, and manage the risks of medicines
The EU Risk Management Plan - a tool to address the uncertainties at the time of approval, and manage the risks of medicines Health care uncertainty assessment workshop Session 3: The challenges of health
Quality check of spontaneous adverse drug reaction reporting forms of different countries y
pharmacoepidemiology and drug safety (2010) Published online in Wiley Online Library (wileyonlinelibrary.com).2004 ORIGINAL REPORT Quality check of spontaneous adverse drug reaction reporting forms of
Belgian Centre for Pharmacotherapeutic Information
Pharmacovigilance and Risk Management Ann Van Ermen Belgian Centre for Pharmacotherapeutic Information (www.bcfi.be be ; www.cbip.be) be) and Belgian Centre for Pharmacovigilance Gent, August 26, 2007
Pharmacovigilance and Patient Safety. Dr M. Roy Jobson Chairperson: Pharmacovigilance Committee of the MCC
Pharmacovigilance and Patient Safety Dr M. Roy Jobson Chairperson: Pharmacovigilance Committee of the MCC Outline Pharmacovigilance The South African Medicines Control Council (MCC) The National Adverse
Guidelines for Detecting & Reporting Adverse Drug Reactions
Guidelines for Detecting & Reporting Adverse Drug Reactions For Healthcare Professionals Rational Drug Use and Pharmacovigilance Department- JFDA (2014) Guidelines for Detecting & Reporting Adverse Drug
Mircea Ciuca, MD Global Head Medical & Clinical Drug Safety
Mircea Ciuca, MD Global Head Medical & Clinical Drug Safety Disclaimer The views and opinions expressed in this presentation are solely those of the presenter and do not necessarily reflect those of Vifor,
Use of RWE in a regulatory context: issues and examples. Rob Hemmings, MHRA
Use of RWE in a regulatory context: issues and examples Rob Hemmings, MHRA Disclaimer I don t particularly like the terms real world data, real world evidence. To be more precise, I will discuss data generated
Post-Marketing Surveillance Studies
Surveillance Part 1 Post-Marketing Surveillance Studies Marcia A. Testa, MPH, PhD Harvard School of Public Health The time period after regulatory approval and after the product can be purchased and used
Pharmacovigilance in Asia: The China Perspectives. Disclaimer
Pharmacovigilance in Asia: The China Perspectives Rebecca Wang, MD, FRCP, FACC Head, Product Development Drug Safety Operation, Asia Pacific Roche Shanghai Disclaimer The views and opinions expressed in
European contribution to the RWD/RWE debate. Alasdair Breckenridge July 2018
European contribution to the RWD/RWE debate Alasdair Breckenridge July 2018 Sources UK Academy of Medical Sciences(AMS) workshops European Medicines Agency (EMA) Innovative Medicines Initiative (IMI) projects
Potential Steps in Active Surveillance
Background The Sentinel System will augment FDA s postmarket safety assessment capabilities by enhancing its capacity to conduct active surveillance at the population level. Conducting active surveillance
Advance Topics in Pharmacoepidemiology. Risk Management. Conflict of Interest Declaration. Benefit Harm Profile?
Advance Topics in Pharmacoepidemiology Risk Management 2012 Mid-Year ISPE Meeting Miami, April 21-23, 2012 Ariel E., Arias MD, PhD - Fac. Pharmacy; Université de Montréal - Biologics & Genetic Therapies
The Need for National Pharmacovigilance Program
The Need for National Pharmacovigilance Program ANAS BAHNASSI Presented at Order of Lebanese Pharmacists on March 10 th 2018 All drugs are dangerous Some are also useful. N. Moore, BMJ, 2005, 330;539-540
Measuring Potential Return on Investment in Pharmacovigilance: A Framework
Measuring Potential Return on Investment in Pharmacovigilance: A Framework Andy Stergachis, PhD Professor, Epidemiology & Global Health Director, Global Medicines Program Joseph Babigumira, MD, PhD Assistant
In this video you will hear about pharmacovigilance, what it means and the role of the European Medicines Agency
In this video you will hear about pharmacovigilance, what it means and the role of the European Medicines Agency But first let s define what pharmacovigilance is Pharmacovigilance is about monitoring the
2 Pharmacovigilance. 2.1 Fundamentals of Pharmacovigilance
Pharmacovigilance 2 Pharmacovigilance 2 In this chapter, the fundamentals of pharmacovigilance are outlined with a particular emphasis on the role of healthcare professionals in reporting adverse drug
Update on Real World Evidence Data Collection
Update on Real World Evidence Data Collection STAMP, 10 March 2016 Presented by Dr Peter Arlett EMA An agency of the European Union What is Real-world evidence? Big data = umbrella term describing large
Legislative and Regulatory Modernization for Therapeutic Products
Legislative and Regulatory Modernization for Therapeutic Products Maurica Maher Associate Director, Office of Legislative and Regulatory Modernization, Health Products and Food Branch, Health Canada Presented
Overview of FDA s Sentinel Initiative
Overview of FDA s Sentinel Initiative Judy Racoosin, Sentinel Initiative Scientific Lead, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration September
Public Consultation Paper: Assessment of the Functioning of the Clinical Trials Directive 2001/20/EC
Public Consultation Paper: Assessment of the Functioning of the Clinical Trials Directive 2001/20/EC National Institute for Health Research (NIHR CRN) and UKCRC Registered Clinical Trials Units Response
Global Issue & Regulatory Control of Pharmacovigilance System: A Standard Operating Procedure for a New Develop Organization
Global Issue & Regulatory Control of Pharmacovigilance System: A Standard Operating Procedure for a New Develop Organization Rajendra Kr. Songara, Birendra Shrivastava, Deepak M Gupta *, Rajeev K Singla
Zimbabwe National Pharmacovigilance Policy and Guidelines Handbook
Zimbabwe National Pharmacovigilance Policy and Guidelines Handbook November 2013 106 Baines avenue Phone: +263-4-708255/792165 P.O Box 10559 Fax: +263-4-736980 Harare Zimbabwe Email: mcaz@mcaz.co.zw website:
Surveillance Part 2. Marcia A. Testa, MPH, PhD Harvard School of Public Health
Surveillance Part 2 Marcia A. Testa, MPH, PhD Harvard School of Public Health Periodic Population-based Surveys Used for surveillance if surveys are repeated on a regular basis Careful attention to the
Zimbabwe National Pharmacovigilance Policy Handbook
Zimbabwe National Pharmacovigilance Policy Handbook 2 nd Edition, December 2016 106 Baines Avenue Tel: +263-4-708255/792165/736981 In collaboration with the Ministry Harare Mobile: +263 772145191/2/3 of
COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE WITH PHARMACOVIGILANCE REGULATORY OBLIGATIONS
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 15 November 2001 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE
PHARMACOVIGILANCE METRICS
PHARMACOVIGILANCE METRICS Andy Stergachis, PhD, RPh Professor of Epidemiology and Global Health Director, Global Medicines Program University of Washington, Seattle, WA stergach@uw.edu MEASURING PERFORMANCE
Saudi FDA Drug Approval Process. Dr. Mohammed A. Alquwaizani Consultant- Chief of the scientific office Saudi Food and Drug Authority
Saudi FDA Drug Approval Process Dr. Mohammed A. Alquwaizani Consultant- Chief of the scientific office Saudi Food and Drug Authority Objective Describe the drug regulation practice in Saudi Arabia and
Regulatory challenges and opportunities for the use of Real World Evidence for drug registration and labelling
Presentation title Date 1 Regulatory challenges and opportunities for the use of Real World Evidence for drug registration and labelling Marianne Bork Samuelsen, Msc Pharm Regulatory Affairs Novo Nordisk
VOLUME 9 - PHARMACOVIGILANCE. Medicinal Products for Human and Veterinary Use
VOLUME 9 - PHARMACOVIGILANCE Medicinal Products for Human and Veterinary Use FOREWORD Directive 75/319/EEC as amended by Commission Directive 2000/38/EC of 5 th June 2000 and Directive 81/851/EEC as amended
Guidance for Industry, Review Staff, and the Clinical Community
Guidance for Industry, Review Staff, and the Clinical Community Guidance on Criteria and Approaches for Postmarket Surveillance Document Issued on: November 2, 1998 U.S. Department of Health and Human
NIS Considerations - Bulgaria
NIS Considerations - Bulgaria An overview of the considerations when conducting Noninterventional Studies in Bulgaria Stuart McCully CHCUK Ltd NIS-C-BG-2014 1 Table of Contents Disclaimer 5 Copyright 5
CBA Workshop Series -3 Drug Safety (Pharmacovigilance) and Big Data. Larry Liu TCONNEX Inc.
CBA Workshop Series -3 Drug Safety (Pharmacovigilance) and Big Data Larry Liu TCONNEX Inc. Larry.liu@tconnex.com Drug Safety Drug Safety is about Adverse Drug Reaction or ADR ADR is any unintended and
The Monitoring Medicines Project: A Multinational Pharmacovigilance and Public Health Project
Drug Saf (2015) 38:319 328 DOI 10.1007/s40264-015-0283-y SPECIAL ARTICLE The Monitoring Medicines Project: A Multinational Pharmacovigilance and Public Health Project Shanthi N. Pal 1 Sten Olsson 2 Elliot
UK Standards for Pharmacovigilance Departments 2015
UK Standards for Pharmacovigilance Departments 2015 03 UK Standards for Pharmacovigilance Departments 2015 Introduction 1 European legislation (Directive 2010/84/EU; Regulation (EU) No 1235/2010) requires
Post-marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER
Post-marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER CSRC/DIA Think Tank June 3, 2016 Oanh Dang, PharmD, BCPS Division of Pharmacovigilance Safety Evaluator Office of Surveillance and
Safety reporting requirements in the post marketing phase. Pharmacovigilance Specialty Committee SQA Conference March 2017 Washington
Safety reporting requirements in the post marketing phase Pharmacovigilance Specialty Committee SQA Conference March 2017 Washington DISCLAIMER These materials have been prepared solely for educational
Good Vigilance Practice Module VI
Good Vigilance Practice Module VI Management and reporting of adverse reactions to medicinal products Stakeholders forum 27th February 2012 Gilles Touraille Signal Detection and Data Analysis Pharmacovigilance
WHO Pre-Qualification Programme: Facilitating Regional Approval and Patient Access to Treatments
WHO Pre-Qualification Programme: Facilitating Regional Approval and Patient Access to Treatments A Decade of R&D for Neglected Diseases in Africa Nairobi, Kenya, 4-5 June 2013 Hiiti B. Sillo Director General
Risk Management Plan Guidance
1 / 17 Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Translated by Office of Safety Ⅰ, Pharmaceuticals and Medical Devices Agency This English version is intended to be
A Study on Regulatory Requirements of Risk Management Plan for Pharmaceuticals in Europe, U.S. and Brazil
A Study on Regulatory Requirements of Risk Management Plan for Pharmaceuticals in Europe, U.S. and Brazil Ravindra S. Trivedi, Darshil B. Shah *, Dilip G. Maheshwari INDO GLOBAL JOURNAL OF PHARMACEUTICAL
RWE from pre-clinical to launch. RWE from pre-clinical to launch. Standard of care Unmet needs. Disease burden Budget impact.
Real Real World World Data Data Across Across the the Product Product Lifecycle: Lifecycle: RWE from pre-clinical to launch RWE from pre-clinical to launch Standard of care Unmet needs Disease burden Budget
Recording, Managing and Reporting Adverse Events in the UK
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
Professor Kimme Hyrich, MD, PhD, FRCPC, UK
GaBI Scientific Meetings 26 January 2017, Pullman London St Pancras, London, UK ROUNDTABLE ON REGISTRIES Practical Considerations for Registries making them work Professor Kimme Hyrich, MD, PhD, FRCPC,
Adverse Event Reporting
Adverse Event Reporting AE Case Receipt When we receive a case, we induct it through a well-oiled process that reduces the number of subsequent queries, classifies events appropriately, and increases the
Pharmacovigilance & Signal Detection
Pharmacovigilance & Signal Detection 30 th International Conference on Pharmacoepidemiology & Therapeutic Risk Management Pre-conference educational session Thursday, October 23, 2014; 2:00-6:00pm Semi-automated,
What s New in GCP? FDA Clarifies, Expands Safety Reporting Guidance
Vol. 9, No. 2, February 2013 Happy Trials to You What s New in GCP? FDA Clarifies, Expands Safety Reporting Guidance Reprinted from the Guide to Good Clinical Practice with permission of Thompson Publishing
OMICS Group. Contact us at:
OMICS Group OMICS Group International through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community. OMICS Group hosts over 400 leading-edge peer
Pharmacovigilance Practice in Pharmaceutical Industry. From Adverse Event Collection Risk Management
Pharmacovigilance Practice in Pharmaceutical Industry From Adverse Event Collection Risk Management Hani Mickail, MD Head Global Clinical Safety Operations - Novartis Pharmacovigilance Workshop 23-24 October
Initial Draft Discussion Document for A Canadian Orphan Drug Regulatory Framework
Initial Draft Discussion Document for A Canadian Orphan Drug Regulatory Framework Table of Contents Preamble... 3 Background... 3 What is a rare disease?... 3 What is an orphan drug?... 3 Unique Challenges
Regulatory Considerations and Evolving Issues Concerning REMS Programs
Regulatory Considerations and Evolving Issues Concerning REMS Programs Kathleen M. Sanzo ksanzo@morganlewis.com 202-739 739-5209 August 2009 1 Evolution of Risk Management AT FDA 1976 Patient package inserts
The Right Data for the Right Questions:
The Right Data for the Right Questions: Evidentiary Needs as a Guide to Data Source Selection David Thompson, PhD Senior Vice President Louise Parmenter, PhD Global Head of Operations Real-World & Late
Screening for adverse reactions in EudraVigilance
Screening for adverse reactions in EudraVigilance Basel Biometric Society meeting, 29 th November 2016 Gianmario Candore Data Standardisation and Analytics (EMA) An agency of the European Union Disclaimer
Safety Reporting Part 1: For Clinical Trials of Investigational Medicinal Products (CTIMPs)
Part 1: For Clinical Trials of Investigational Medicinal Products (CTIMPs) Version 1.4 Effective date: 1 December 2011 Author: Approved by: Claire Daffern, QA Manager Dr Sarah Duggan, CTU Manager Revision
Traceability of biopharmaceuticals in spontaneous reporting systems
1 Traceability of biopharmaceuticals in spontaneous reporting systems Credits to Niels Vermeer (UU/MEB) Marieke De Bruin (UU/MEB) Sabine Straus (MEB/ ErasmusmMC) Aukje Mantel-Teeuwisse (UU) Toine Egberts
PHARMA CONGRESS. Pharmacovigilance and Drug Safety: Assessing Future Regulatory and Compliance Developments. October 28, 2008
PHARMA CONGRESS October 28, 2008 Pharmacovigilance and Drug Safety: Assessing Future Regulatory and Compliance Developments Beverly H. Lorell, MD Senior Medical & Policy Advisor King & Spalding LLP Assessing
PROACTIVE PHARMACOVIGILANCE
PROACTIVE PHARMACOVIGILANCE RISK BENEFIT A New Model for the 21st Century 21st century technologies will create significant opportunities and challenges for all health care stakeholders. Pharmacovigilance
Are Pharmaco- and Medical Device Vigilance the same?
Are Pharmaco- and Medical Device Vigilance the same? And the new Medical Device Regulation (MDR) Benelux Pharmacovigilance Day, 17 Oct 2017 Jan Bart Hak COMPANY Qualified & Experienced Staff Divisions
Vaccine Safety Monitoring, Reporting and Analysis. GBC 2017, Yun Chon, Ph. D
Vaccine Safety Monitoring, Reporting and Analysis GBC 2017, Yun Chon, Ph. D Disclaimer This presentation is based on my own opinion and is not representing the opinion of International Vaccine Institute.
Signal Detection Quantitative Analysis of Safety Data. Dr. Yusuf Tanrikulu Basel, 29th November 2016
Signal Detection Quantitative Analysis of Safety Data Dr. Yusuf Tanrikulu Basel, 29th November 2016 Contents Regulatory background Goals of signal detection Data sources Methods Recent developments 2 Regulatory
Sonja Brajovic Medical Officer, Office of Surveillance and Epidemiology Center for Drug Evaluation and Research Food and Drug Administration
FDA Perspective on MedDRA Coding Quality in Post marketing Safety Reports European Informal MedDRA User Group Webinar Sonja Brajovic Medical Officer, Office of Surveillance and Epidemiology Center for
Finnish Medicines Agency Administrative Regulation PHARMACOVIGILANCE
Administrative regulation 22.5.2013 3427/03.01.01/2012 4/2013 UNOFFICIAL TRANSLATION Finnish Medicines Agency Administrative Regulation PHARMACOVIGILANCE Legal basis Section 30 c subsection 3, section
Contact Information: Rapture Biotech D-201, Sector - 10, Noida Uttar Pradesh. Phone , ,
Topics Covered: MODULE 1 Introduction To Pharmacovigilance Terminologies used in Pharmacovigilance ADRs Polypharmacy MODULE 2 Pharmacoepidemiology Iatrogenesis Prescription-event monitoring MODULE 3 SAE
Use of immunotherapy for cancer treatment
Use of immunotherapy for cancer treatment Pre- and post-licensing considerations Professor Angela Thomas, Pediatric Hematologist Vice Chair Commission on Human Medicines Chair Clinical Trials, Biologicals
Official Letter from DOH
Issued Date 2008/08/19 Issued by DOH Ref. No 0970329838 RE To announce the Guidance for Good Pharmacovigilance Practice Attachment Guidance for Good Pharmacovigilance Practice Official Letter from DOH
INTRODUCTION TO PHARMACOVIGILANCE AND REGULATORY AFFAIRS SPRING 2012
INTRODUCTION TO PHARMACOVIGILANCE AND REGULATORY AFFAIRS SPRING 2012 Course Description: Pharmacovigilance is the science and activities that relate to the detection, monitoring, assessment, understanding
Jeffrey Brown, PhD. November 12, 2013 Department of Population Medicine Harvard Pilgrim Health Care Institute/ Harvard Medical School
info@mini-sentinel.org 1 Biosimilar Collective Intelligence System: Utilizing Data Consortiums to Prove Safety and Effectiveness of Biosimilars Reviewing current landscape of existing data consortiums:
Citation for the original published paper (version of record):
http://www.diva-portal.org Postprint This is the accepted version of a paper published in Patient. This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal
Pharmacovigilance Approach to Challenges with Use of Medicines. Oksana Lebega USAID SIAPS project Antalya, Turkey December 10-13, 2013
Pharmacovigilance Approach to Challenges with Use of Medicines Oksana Lebega USAID SIAPS project Antalya, Turkey December 10-13, 2013 Background Development of Pharmacovigilance (1) Growing market of pharmaceutical
8 th STAMP expert group meeting
8 th STAMP expert group meeting Repurposing: Themes & discussion points from case studies Dr Daniel O Connor MHRA (UK) Repurposing medicines Drug repurposing is the process of identifying a new use for
EUROPEAN PHARMACEUTICAL MARKET RESEARCH ASSOCIATION (EphMRA) RESPONSE TO
EUROPEAN PHARMACEUTICAL MARKET RESEARCH ASSOCIATION (EphMRA) RESPONSE TO IMPLEMENTING MEASURES IN ORDER TO HARMONISE THE PERFORMANCE OF THE PHARMACOVIGILANCE ACTIVITIES PROVIDED FOR IN DIRECTIVE 2001/83/EC
Need for collaboration in pharmacovigilance to ensure effective health protection and promotion
Need for collaboration in pharmacovigilance to ensure effective health protection and promotion Measuring the impact of pharmacovigilance decisions Presented by Jacoline Bouvy on 17 September 2015 Pharmacovigilance
EphMRA Adverse Event Reporting Guidelines 2016
EphMRA Adverse Event Reporting Guidelines 2016 Based upon the Guideline on good pharmacovigilance practices (GVP) Module VI Management and reporting of adverse reactions to medicinal products European
Support of Local Production in Africa The Tanzanian Experience
Support of Local Production in Africa The Tanzanian Experience International Conference on Local Pharmaceutical Production in Africa Cape Town, April 4-6, 2011 German Medical Aid Organisation action medeor
Pharmacovigilance and safety reporting for sponsored ATIMPs/CTIMPs
Joint Research Management Office (JRMO) Standard Operating Procedure (SOP) for: Pharmacovigilance and safety reporting for sponsored ATIMPs/CTIMPs SOP Number: 26a Version Number: 13.0 Effective Date: 31
PUBLIC CONSULTATION ON LEGISLATIVE PROPOSALS FOR PHARMACOVIGILANCE
PATRICK WALLER LTD. Consultancy in Pharmacovigilance and Pharmacoepidemiology 15, Tamella Road, Botley, Southampton SO30 2NY. Tel : 01489 798107 Fax : 01489 690016 e-mail : patrick.waller@btinternet.com
Data Quality in the Real World: Ensuring Integrity across the Medical Device Lifecycle
Data Quality in the Real World: Ensuring Integrity across the Medical Device Lifecycle Moderated by Karen Conway, GHX Panelists: Steven Luxenberg, MD, U.S. FDA CDRH Dennis Black, BD Robert Lynch, Franciscan
Good Pharmacovigilance Practice Tunisian guidelines
Good Pharmacovigilance Practice Tunisian guidelines Introduction Arab ministers of health came to a common decree (number 7) in their 37th regular meeting in March 2012. The Higher Technical Committee
Update on SCOPE - Strengthening Collaborations to. Operate Pharmacovigilance in Europe
Update on SCOPE - Strengthening Collaborations to Operate Pharmacovigilance in Europe Background Review Of The EU System 2 Pharmacovigilance Legislation 2012: EU Pharmacovigilance legislation Directive
EMA - Early Access. PEARRL Annual Meeting 2017-Regulatory Science Symposium. University College Cork, Ireland
EMA - Early Access PEARRL Annual Meeting 2017-Regulatory Science Symposium University College Cork, Ireland Presented by Evangelos Kotzagiorgis Scientific Administrator, Quality of Medicines Office Specialised
An Assessment of the Community System of Pharmacovigilance. European Commission Public Consultation. Call for expression of views
ASSOCIATION EUROPÉENNE DES MÉDECINS DES HÔPITAUX EUROPEAN ASSOCIATION OF SENIOR HOSPITAL PHYSICIANS EUROPÄISCHE VEREINIGUNG DER LEITENDEN KRANKENHAUSÄRZTE EUROPESE VERENIGING VAN STAFARTSEN DEN EUROPÆISKE
SCOPE Work Package 4 ADR Collection. Duplicate Detection: Best Practice Guide
Duplicate Detection: Best Practice Guide Contents Acknowledgments 3 1. Introduction 4 1.1 Background 4 1.2 Definitions and abbreviations 6 2. The duplicate detection process 7 2.1 Detection of duplicate
New pharmacovigilance systems and services
New pharmacovigilance systems and services 17 September 2015, PCWP/HCPWP joint meeting Presented by Peter Arlett, Head of Pharmacovigilance department An agency of the European Union Background The new
KLH-21 version 7 With effect from the date of issue (effective date 20th July 2018), this guideline supersedes guideline KLH-21, version 6.
KLH-21 version 7 Reporting Adverse Reactions to Medicinal Products for Human Use in a Clinical Trial and to Medicinal Products without Marketing Authorisation The guideline is being issued on the basis
Report from the Paediatric Committee on its first anniversary
European Medicines Agency London, 11 July 2008 Doc. Ref. EMEA/PDCO/347884/2008 Report from the Paediatric Committee on its first anniversary The European Medicines Agency s Paediatric Committee (PDCO)
Pharmacovigilance information for pharmaceutical companies
Pharmacovigilance information for pharmaceutical companies Electronic transmission of individual case safety reports (ICSRs) with ANSM (French National Agency for the safety of Medicines and Health Products)
Drug Safety and FDA Revitalization Legislation
Drug Safety and FDA Revitalization Legislation Dan Kracov August 23, 2007 FDA Regulatory and Compliance Symposium House and Senate FDA Revitalization Bills Senate: S. 1082, Food and Drug Administration
EMEA/AD/258: Head of Sector Pharmacovigilance and Risk Management of Medicinal Products for Human Use (AD9).
EMEA/AD/258: Head of Sector Pharmacovigilance and Risk Management of Medicinal Products for Human Use (AD9). Responsible, under the Head of Unit for the Post-Authorisation Evaluation of Medicinal Products
Pharmacovigilance. Interaction with the Regulatory Agency. Murilo Freitas Dias ! "#$ Salvador September 26, 2006
Interaction with the Regulatory Agency Pharmacovigilance! "#$ Salvador September 26, 2006 Drug Safety Knowledge is gained either by experience, learning and perception or through association and reasoning
Sec Short title; finding. Sec Authority to assess and use drug fees. Sec Reauthorization; reporting requirements.
H.R. 2430, FDA Reauthorization Act of 2017 Section 1. Short Title. This Act may be cited as the FDA Reauthorization Act of 2017. Section 2. Table of Contents Table of Contents TITLE I: FEES RELATING TO
11.1 TRACKING COMMODITY FINANCIAL FLOWS
FIGURE 11-1. THE LOGISTICS CYCLE THE LOGISTICS CYCLE CHAPTER 11 FINANCING Serving Customers Cost of the health care products that are required by the health care system Source of funding for these products
Effective application of Risk Management techniques to Drug Safety: a pragmatic approach
Effective application of Risk Management techniques to Drug Safety: a pragmatic approach Dr Mark Perrott WCI Consulting ltd 19th October 2009 1 Disclaimer The views and opinions expressed in the following
Doc. No. DPS/GDL/034 Revision No.: 0 Effective Date: 26 April 2018 Review-Due Date: 26 April 2021
National Drug Authority Head Office Rumee Towers Plot 19, Lumumba Avenue P. O. Box 23096 Kampala, Uganda Tel: 256-0414 - 255665/347391/2 E-mail: ndaug@nda.or.ug Website: http://www.nda.or.ug Doc. No. DPS/GDL/034